- InteRNA Technologies, The Netherlands-based company that designs new therapies tackling cancer, closed an extended Series B financing round amounting to €18.5M in total
- This Series B round led by AurorA Science, an Italian biotech investment company, along with existing investor Waterman Ventures
- Current shareholders Aglaia Oncology Funds and OostNL also contributed to the financing round
- The funding will enable the clinical evaluation of the company’s microRNA lead candidate, INT-1B3, in patients with advanced solid tumors
- Furthermore, the proceeds will used to develop and advance additional proprietary preclinical drug candidates adressing a variety of cancer indications thereby expanding InteRNA’s pipeline
- The company’s microRNA lead candidate, INT-1B3, has a mechanism of action that addresses multiple hallmarks of cancer simultaneously
